Stacy Newberry, APRN
Nurse Practitioner · Tulsa, OKNPI 1841775947
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $19,450 of the $28,154 with a category attached, or 69.1%. AstraZeneca accounts for 72.1% of it on its own, with 27 other manufacturers making up the rest. 2025 is the largest year on record at $15,505, more than ten times the $436 reported in 2021. Among nurse practitioner clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 148 payments — averaging $190.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$20K
- Daiichi Sankyo Inc.$5K
- Johnson & Johnson$527
- Takeda Pharmaceuticals U.S.A., Inc.$517
- Astellas Pharma US Inc$472
- Seagen Inc.$213
- plus $2K from 22 others
What the payments were for
- Speaking & faculty fees$19,45069%
- Travel & lodging$3,06311%
- Food & beverage$4,64516%
- Education$9964%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 53 | $20,311 |
| Daiichi Sankyo Inc. | 18 | $4,561 |
| Johnson & Johnson(2 entities) | 8 | $527 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $517 |
| Astellas Pharma US Inc | 6 | $472 |
| Seagen Inc. | 7 | $213 |
| E.r. Squibb & Sons, L.L.C. | 5 | $211 |
| Incyte Corporation | 3 | $191 |
| Lilly USA, LLC | 4 | $171 |
| Regeneron Healthcare Solutions, Inc. | 4 | $164 |
| Pfizer | 7 | $123 |
| Bayer | 2 | $121 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $105 |
| AbbVie | 4 | $68 |
| Novartis | 2 | $48 |
| Sanofi | 2 | $46 |
| Ipsen Biopharmaceuticals, Inc | 2 | $42 |
| Bristol Myers Squibb | 2 | $42 |
| Gilead | 2 | $36 |
| Genentech USA, Inc. | 2 | $31 |
| AVEO Pharmaceuticals, Inc. | 2 | $27 |
| Pharmaessentia USA Corporation | 1 | $23 |
| Novo Nordisk | 1 | $22 |
| Genmab U.S., Inc. | 1 | $20 |
| Blueprint Medicines Corporation | 1 | $19 |
| Amgen | 1 | $16 |
| Merck | 1 | $14 |
| Kyowa Kirin, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$28,154 in reported general payments places this provider in the 95th percentile of 824 nurse practitioner providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Potassium Chloride | 27 | $529 |
| Alendronate Sodium | 12 | $303 |
| Omeprazole | 11 | $153 |
| Levofloxacin | 12 | $63 |
Paid to pharmacies, not to this prescriber.
Other nurse practitioner in Tulsa
- Jenny GuthrieTulsa$106K
- Amanda SmallTulsa$14K
- Mindi PriceTulsa$11K
- Huong HuynhTulsa$10K
- Jonathan BouldinTulsa$10K
- Michelle LoeberTulsa$10K
- Erin WilliamsonTulsa$9K
- Andrea CarpenterTulsa$7K
- Charles SpradlinTulsa$7K
- Leslie BurtonTulsa$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.